Skip to content
PepFinder

KPV

KPV is a three-amino-acid peptide (lysine-proline-valine) that matches the final three residues of alpha-melanocyte-stimulating hormone (α-MSH). It has shown anti-inflammatory effects in cell studies and in mouse models of colitis. No human trial of KPV has been published, and it is not an approved medicine.

By the PepFinder editorial team · Reviewed 23 Sept 2026 · Editorial independence

KPV suppliers and prices

Compare all KPV prices →

77 suppliers in our directory list KPV. Median price per mg: US$5.70 (28 suppliers pricing in USD), £4.24 (16 suppliers pricing in GBP), CA$5.50 (10 suppliers pricing in CAD), A$8.30 (8 suppliers pricing in AUD). Prices are compared only within the same currency.

Ranked by PepFinder rating; payment never changes the order. By country: United Kingdom · United States · Canada · Australia · New Zealand

What it is

KPV is a tripeptide made of lysine, proline and valine. It is the last three amino acids of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid hormone involved in skin pigmentation and inflammation, whose full sequence is SYSMEHFRWGKPV [1]. Researchers became interested in KPV because it appeared to keep much of α-MSH’s anti-inflammatory activity without the pigment-stimulating effect, since it lacks the part of α-MSH needed to bind the known melanocortin receptors [3].

KPV is sometimes confused with melanotan II and PT-141, which are also derived from α-MSH. Those are larger synthetic peptides designed to act on melanocortin receptors; KPV is not.

How it is thought to work

In a 2003 mouse study of crystal-induced peritonitis, KPV reduced the build-up of white blood cells, but unlike α-MSH it did not raise cAMP in macrophages, and its effect was not blocked by a melanocortin receptor antagonist. The authors concluded KPV probably works through inhibition of interleukin-1β rather than through melanocortin receptors [2].

Gut research points to a transporter called PepT1, which carries small peptides into cells and is increased in the inflamed colon. In a 2008 study, nanomolar concentrations of KPV reduced activation of the inflammatory NF-κB and MAP kinase pathways in human intestinal cells and T cells, and its uptake depended on PepT1 [4]. Earlier laboratory work also reported that α-MSH and KPV inhibited Staphylococcus aureus and Candida albicans in culture [1].

What the research shows

All published efficacy evidence for KPV comes from cell and animal studies. In mouse colitis induced by the chemicals DSS or TNBS, KPV given in drinking water reduced inflammation and inflammatory cytokine levels [4]. A separate 2008 study found that KPV sped recovery and reduced inflammatory infiltrates in DSS colitis and in a T-cell transfer colitis model in mice, and rescued all treated mice lacking a functional melanocortin-1 receptor from death during DSS colitis [5].

Later work has focused on delivery. In a 2017 study, KPV loaded into hyaluronic-acid-coated nanoparticles and given by mouth in a hydrogel reduced mucosal damage and TNF-α in a mouse model of ulcerative colitis [6]. These are formulation experiments in mice and do not show effects in people.

Human studies

We found no published human trial of KPV. The FDA has stated that it had not identified any human exposure data on drug products containing KPV [7].

Doses used in published research

Cell studies used nanomolar concentrations of KPV [4]. In mice, KPV has been given in drinking water [4] and in nanoparticle formulations by mouth [6]. These are animal and laboratory conditions, and no human dose has been established. The peptide calculator converts vial contents to concentrations but does not indicate an appropriate amount.

Safety and side effects reported

There are no human safety data for KPV. The FDA has said it cannot determine whether KPV would cause harm if given to people because no human exposure data have been identified [7]. The 2017 nanoparticle study reported that its KPV-loaded particles appeared non-toxic to intestinal cells [6], but cell and mouse findings do not establish safety in humans.

Regulatory status

KPV is not approved as a medicine anywhere we are aware of. In the US, the FDA previously placed KPV in category 2 of its interim compounding policy, the list of bulk substances that may present significant safety risks; the nomination was later withdrawn and the FDA now lists it among substances previously in category 2 [7].

On 23 July 2026, the FDA’s Pharmacy Compounding Advisory Committee considered KPV for wound healing and inflammatory conditions [9]. STAT reported that it voted to recommend adding it to the list of substances US pharmacies may compound. The FDA had not posted the votes when we checked, the vote is not binding, and as of September 2026 we have not confirmed a final FDA decision [8]. We have not confirmed KPV’s status on the WADA Prohibited List. For national rules, see our legal status overview and the US page.

Storage and handling

KPV is sold as a freeze-dried powder. Peptides are generally stored cold, dry and away from light, and reconstituted solutions are refrigerated and used within a limited period. See how to store peptides.

Buying and testing

References

  1. [1] Cutuli M, Cristiani S, Lipton JM, Catania A Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000. PubMed 10670585
  2. [2] Getting SJ, Schiöth HB, Perretti M Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003. PubMed 12750433
  3. [3] Brzoska T, Böhm M, Lügering A, et al. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol. 2010. PubMed 21222263
  4. [4] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PubMed 18061177
  5. [5] Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. PubMed 18092346
  6. [6] Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017. PubMed 28143741
  7. [7] US Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page last updated 22 April 2026). FDA. 2026. Source
  8. [8] STAT News FDA panel backs compounded BPC-157, KPV peptides (23 July 2026). STAT. 2026. Source
  9. [9] US Food and Drug Administration July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA. 2026. Source

Frequently asked questions

What is KPV?

KPV is a tripeptide of lysine, proline and valine that matches the last three amino acids of the hormone α-MSH. It has anti-inflammatory effects in cell and mouse studies.

Has KPV been tested in humans?

No published human trial of KPV was found, and the FDA has said it identified no human exposure data for KPV products.

Does KPV cause tanning like melanotan?

KPV lacks the part of α-MSH needed to bind melanocortin receptors, and researchers describe it as lacking pigment-stimulating activity. Melanotan II is a different, receptor-targeting peptide.

What has KPV been studied for?

Mainly inflammatory bowel disease, using mouse models of colitis, along with cell studies of inflammation and microbial growth.

Is KPV FDA-approved?

No. In July 2026 an FDA advisory committee reportedly voted to recommend allowing US pharmacies to compound KPV, but that vote is not binding and is not an approval.

Related

PepFinder is an independent directory. We do not sell peptides, and nothing here is medical advice. Research peptides are not licensed medicines. Suppliers cannot pay to change what we write. Spotted an error? Email editorial@pepfinder.com.